PL4069278T3 - Sposoby i kompozycje do zapobiegania cukrzycy typu 1 - Google Patents

Sposoby i kompozycje do zapobiegania cukrzycy typu 1

Info

Publication number
PL4069278T3
PL4069278T3 PL20896240.7T PL20896240T PL4069278T3 PL 4069278 T3 PL4069278 T3 PL 4069278T3 PL 20896240 T PL20896240 T PL 20896240T PL 4069278 T3 PL4069278 T3 PL 4069278T3
Authority
PL
Poland
Prior art keywords
diabetes
prevention
compositions
methods
type
Prior art date
Application number
PL20896240.7T
Other languages
English (en)
Inventor
Mary S. MORRIS
Original Assignee
Dr. Mary Morris & Associates, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Mary Morris & Associates, Llc filed Critical Dr. Mary Morris & Associates, Llc
Publication of PL4069278T3 publication Critical patent/PL4069278T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL20896240.7T 2019-12-06 2020-11-25 Sposoby i kompozycje do zapobiegania cukrzycy typu 1 PL4069278T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962944503P 2019-12-06 2019-12-06
PCT/US2020/062159 WO2021113136A1 (en) 2019-12-06 2020-11-25 Methods and compositions for the treatment and prevention of type 1 diabetes

Publications (1)

Publication Number Publication Date
PL4069278T3 true PL4069278T3 (pl) 2025-10-06

Family

ID=76222225

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20896240.7T PL4069278T3 (pl) 2019-12-06 2020-11-25 Sposoby i kompozycje do zapobiegania cukrzycy typu 1

Country Status (12)

Country Link
US (1) US12551537B2 (pl)
EP (2) EP4623900A3 (pl)
JP (1) JP2023505190A (pl)
CN (1) CN115151273A (pl)
AR (1) AR122339A1 (pl)
AU (1) AU2020398147A1 (pl)
CA (1) CA3159054A1 (pl)
DK (1) DK4069278T3 (pl)
FI (1) FI4069278T3 (pl)
PL (1) PL4069278T3 (pl)
TW (1) TW202133876A (pl)
WO (1) WO2021113136A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4069278T3 (pl) * 2019-12-06 2025-10-06 Dr. Mary Morris & Associates, Llc Sposoby i kompozycje do zapobiegania cukrzycy typu 1
AU2021356578A1 (en) * 2020-10-08 2023-05-11 Dr. Mary Morris & Associates, Llc Methods and compositions for the treatment and prevention of type 1 diabetes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5487898A (en) 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
EP1523993A1 (en) * 1999-12-16 2005-04-20 Eli Lilly & Company Polypeptide compositions with improved stability
PT1242121E (pt) 1999-12-16 2005-05-31 Lilly Co Eli Composicoes polipeptidicas com estabilidade melhorada
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
CN1836047B (zh) 2003-06-17 2010-12-22 赛姆生物系统遗传公司 在植物中生产胰岛素的方法
US20070027063A1 (en) 2004-01-12 2007-02-01 Mannkind Corporation Method of preserving the function of insulin-producing cells
WO2005076965A2 (en) 2004-02-04 2005-08-25 The Trustees Of Columbia University In The City Of New York Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity
DE602005014962D1 (de) * 2004-03-12 2009-07-30 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
WO2006132530A2 (en) * 2005-01-31 2006-12-14 Leiden University Medical Center Methods and means for use in diagnostics and treatment of diabetes
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2012104834A1 (en) * 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
CA2870399A1 (en) 2012-04-16 2013-10-24 Alk-Abello A/S Plant profilin polypeptides for use in non-specific allergy immunotherapy
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US11331376B2 (en) * 2014-11-04 2022-05-17 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
CA3011331C (en) 2016-01-14 2025-05-13 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
CN110446496A (zh) * 2017-02-03 2019-11-12 范德比尔特大学 用于治疗糖尿病的系统、组合物和方法
CN110366412A (zh) 2017-02-28 2019-10-22 生物林格斯Ip有限公司 用于经舌下和颊递送的基于油的制剂
EP3418738A1 (en) 2017-06-23 2018-12-26 Klinikum rechts der Isar der Technischen Universität München A ratio of immune cells as prognostic indicator of therapeutic success in allergen-specific immunotherapy
IL273016B2 (en) 2017-09-08 2024-10-01 Diamyd Medical Ab Genotype stratification in diabetes treatment and prevention
PL4069278T3 (pl) * 2019-12-06 2025-10-06 Dr. Mary Morris & Associates, Llc Sposoby i kompozycje do zapobiegania cukrzycy typu 1
AU2021356578A1 (en) * 2020-10-08 2023-05-11 Dr. Mary Morris & Associates, Llc Methods and compositions for the treatment and prevention of type 1 diabetes

Also Published As

Publication number Publication date
TW202133876A (zh) 2021-09-16
DK4069278T3 (da) 2025-06-30
AU2020398147A1 (en) 2022-06-02
CN115151273A (zh) 2022-10-04
EP4623900A2 (en) 2025-10-01
EP4069278B1 (en) 2025-06-11
EP4069278A1 (en) 2022-10-12
US20230018324A1 (en) 2023-01-19
WO2021113136A1 (en) 2021-06-10
EP4069278A4 (en) 2024-01-10
AR122339A1 (es) 2022-09-07
JP2023505190A (ja) 2023-02-08
FI4069278T3 (fi) 2025-07-16
CA3159054A1 (en) 2021-06-10
US12551537B2 (en) 2026-02-17
EP4623900A3 (en) 2025-12-10

Similar Documents

Publication Publication Date Title
IL285008A (en) Methods for the production and use of myceliated amino acid-supplemented food compositions
SG11202107325TA (en) Methods and compositions for the treatment of fabry disease
SG11202101777VA (en) Methods and compositions for the modification of plants
IL288024A (en) Methods and preparations for the prevention of type 1 diabetes
GB202017593D0 (en) Compositions and methods and uses relating thereto
SI3979827T1 (sl) Hranilna sestava, ki vsebuje 2'fukozilaktozo in 3'galaktozilaktozo
GB201904373D0 (en) Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
PL3930686T3 (pl) Nowatorskie kompozycje żelaza oraz sposoby ich wytwarzania i stosowania
IL290325A (en) Biopharmaceutical preparations and related methods
PL4069278T3 (pl) Sposoby i kompozycje do zapobiegania cukrzycy typu 1
HUE072223T2 (hu) Trisz-amid vegyületek és azokat tartalmazó készítmények
SG11202109278YA (en) Novel mogrosides and uses of the same
IL276783A (en) The composition and pharmaceutical compound containing it
GB201909298D0 (en) Novel compositions and uses thereof
IL287316A (en) compounds and preparations
EP4054558A4 (en) METHODS AND COMPOSITIONS FOR TREATING TYPE 2 DIABETES
ZA202104261B (en) Combination pharmaceutical compositions and methods thereof
ZA202107513B (en) Compounds and compositions comprising the same for treating hypertension or heart failure
EP4058043A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CROHN’S DISEASE
SG11202108262VA (en) Bacterialcidal methods and compositions
GB201907230D0 (en) Compounds and compositions and uses thereof
EP3873601A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION OF TYPE 1 DIABETES
GB2586313B (en) Compositions and methods and uses relating thereto
HK40089082A (en) Methods and compositions for the treatment and prevention of type 1 diabetes
GB201907351D0 (en) Compositions and uses thereof